Vyleesi® (bremelanotide injection) for HSDD | Official HCP Site
Time 2022-09-10 00:29:09Web Name: Vyleesi® (bremelanotide injection) for HSDD | Official HCP Site
WebSite: http://www.vyleesipro.com
ID:309900
Keywords:
injection,for,Vyleesi,bremelanotideDescription:
For US healthcare professionals only.
Patient Site Full Prescribing Information Rx Form FAQsFor US healthcare professionals only.
Not actual patient.
For her hypoactive sexual desire disorder (HSDD)
Introduce her to control
Not actual size.
Vyleesi is the first and only as-needed treatment that has been FDA approved for premenopausal women with acquired, generalized HSDD1
Get her started now
Vyleesi at a glance
SIGNIFICANT IMPROVEMENTS IN THE DEFINING SYMPTOMS OF HSDD
Women saw an increase in sexual desire and decrease in associated distress1
Discover the full efficacy
DEMONSTRATED
SAFETY PROFILE
Most common adverse reactions were reported to be mild to moderate in intensity and transient1
Learn about safety
PATIENT TAKES WHEN
SHECHOOSES
Administer at least 45 minutes prior to sexual activity, not more than one dose in 24 hours, and not more than 8 doses per month1
See as-needed dosing
Here are the resources you’ll need to help her call the shots
Let’s go
INDICATION
VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance.Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.
Limitations of Use
VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance.IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease.
WARNINGS AND PRECAUTIONS
Transient Increase in Blood Pressure and Decrease in Heart Rate: VYLEESI transiently increases blood pressure and reduces heart rate after each dose. Advise patients that these changes usually resolve within 12 hours. VYLEESI is not recommended in patients at high risk for cardiovascular disease. Consider the patient’s cardiovascular risk before initiating VYLEESI and periodically during treatment and ensure blood pressure is well-controlled. To minimize the risk of more pronounced blood pressure effects, patients should not take more than one VYLEESI dose within 24 hours. Patients should not use more than 8 VYLEESI doses per month.
Focal Hyperpigmentation: Reported by 1% of patients who received up to 8 doses per month, including involvement of the face, gingiva and breasts. Patients are at higher risk of developing focal hyperpigmentation if they have darker skin and with daily dosing. Resolution of the focal hyperpigmentation was not confirmed in all patients after discontinuation of VYLEESI. Consider discontinuing VYLEESI if hyperpigmentation develops.
Nausea: Reported by 40% of patients who received up to 8 monthly doses, requiring anti-emetic therapy in 13% of patients and leading to premature discontinuation for 8% of patients. Nausea improves for most patients with the second dose. Consider discontinuing VYLEESI or initiating anti-emetic therapy for persistent or severe nausea.
ADVERSE REACTIONS
Most common adverse reactions (incidence >4%) are nausea, flushing, injection site reactions, headache, and vomiting.
DRUG INTERACTIONS
VYLEESI may slow gastric emptying and impact absorption of concomitantly administered oral medications. VYLEESI may significantly decrease the systemic exposure of orally-administered naltrexone; avoid use with orally administered naltrexone-containing products intended to treat alcohol or opioid addiction.
PREGNANCY
Advise patients to discontinue VYLEESI if pregnancy is suspected. Advise patients to use effective contraception while taking VYLEESI.
A pregnancy exposure registry monitors pregnancy outcomes in women exposed to VYLEESI during pregnancy. Pregnant women exposed to VYLEESI and healthcare providers are encouraged to call the VYLEESI Pregnancy Exposure Registry at 1-800-972-5220.
Please see full Prescribing Information.
Reference: 1. VYLEESI [package insert]. Cranbury, NJ: Palatin Technologies, Inc.; 2021.
INDICATION
VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease.
INDICATION
VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance.Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.
Limitations of Use
VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance.IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
VYLEESI is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease.
WARNINGS AND PRECAUTIONS
Transient Increase in Blood Pressure and Decrease in Heart Rate: VYLEESI transiently increases blood pressure and reduces heart rate after each dose. Advise patients that these changes usually resolve within 12 hours. VYLEESI is not recommended in patients at high risk for cardiovascular disease. Consider the patient’s cardiovascular risk before initiating VYLEESI and periodically during treatment and ensure blood pressure is well-controlled. To minimize the risk of more pronounced blood pressure effects, patients should not take more than one VYLEESI dose within 24 hours. Patients should not use more than 8 VYLEESI doses per month.
Focal Hyperpigmentation: Reported by 1% of patients who received up to 8 doses per month, including involvement of the face, gingiva and breasts. Patients are at higher risk of developing focal hyperpigmentation if they have darker skin and with daily dosing. Resolution of the focal hyperpigmentation was not confirmed in all patients after discontinuation of VYLEESI. Consider discontinuing VYLEESI if hyperpigmentation develops.
Nausea: Reported by 40% of patients who received up to 8 monthly doses, requiring anti-emetic therapy in 13% of patients and leading to premature discontinuation for 8% of patients. Nausea improves for most patients with the second dose. Consider discontinuing VYLEESI or initiating anti-emetic therapy for persistent or severe nausea.
ADVERSE REACTIONS
Most common adverse reactions (incidence >4%) are nausea, flushing, injection site reactions, headache, and vomiting.
DRUG INTERACTIONS
VYLEESI may slow gastric emptying and impact absorption of concomitantly administered oral medications. VYLEESI may significantly decrease the systemic exposure of orally-administered naltrexone; avoid use with orally administered naltrexone-containing products intended to treat alcohol or opioid addiction.
PREGNANCY
Advise patients to discontinue VYLEESI if pregnancy is suspected. Advise patients to use effective contraception while taking VYLEESI.
A pregnancy exposure registry monitors pregnancy outcomes in women exposed to VYLEESI during pregnancy. Pregnant women exposed to VYLEESI and healthcare providers are encouraged to call the VYLEESI Pregnancy Exposure Registry at 1-800-972-5220.
Please see full Prescribing Information.
Speak with a Rep
to learn more about Vyleesi
TAGS:injection for Vyleesi bremelanotide
<<< Thank you for your visit >>>
Websites to related : Strata Geosystems | Geosynthetic
GSE For Sale - Airport Equipment
Skip to content GSE FOR SALE
Billigste Forbrukslån På DagenSkip to the content
Treatment Resources - Upper MidwCall: (651) 702-2692 PartnersAbout UsCase StudiesLinksContact Us
EAA ForumsRegisterHelp ForumNew PostsFAQCalendarForum ActionsMark Forums ReadQuick LinksToday's PostsView Site LeadersWhat's New?Advanced SearchForum EAA For
Vigamus Academy - Università deCorsiGame Design & DevelopmentGrafica 3D, Concept Art & Animation per VideogiochiSummer SchoolLocalizzazioneLaureaRicercaSviluppoPartn
Montagne Leaders - L’informatioSkip to content| En continu |28 / 06 Fabien Felli succède à Jean Souchal à la présidence de POMA08 / 04 Michel Drapier s’en est allé15 / 03 Bart
Andrea Parbono • ConsulenteConsulente Informatico chi sono di cosa mi occupo
Home - Genova for YachtingVai al contenutoGenova for YachtingItalianoEnglishItalianoEnglishHOMEASSOCIAZIONEPresentazioneDomande FrequentiAZIENDESTUDIOJOB CENTERNEWSCONTATTIAsso
ThinkUpLab – Creatività | Cons Vai al contenuto THINKUPLABTHINK
UPLABCREATIVITÀ | CONSULENZA | FORMAZIONEminimal-arrow-tulCREATIVITÀminimal-arrow-tulCONSULENZAminimal-
Hot Websites